<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34119671</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-3441</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>166</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</Title>
          <ISOAbbreviation>Eur J Pharm Biopharm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>"Felodipine-indomethacin" co-amorphous supersaturating drug delivery systems: "Spring-parachute" process, stability, in vivo bioavailability, and underlying molecular mechanisms.</ArticleTitle>
        <Pagination>
          <StartPage>111</StartPage>
          <EndPage>125</EndPage>
          <MedlinePgn>111-125</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejpb.2021.05.030</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0939-6411(21)00169-7</ELocationID>
        <Abstract>
          <AbstractText>Amorphous solid dispersions (ASD) are one of most commonly used supersaturating drug delivery systems (SDDS) to formulate insoluble active pharmaceutical ingredients. However, the development of polymer-guided stabilization of ASD systems faces many obstacles. To overcome these shortcomings, co-amorphous supersaturable formulations have emerged as an alternative formulation strategy for poorly soluble compounds. Noteworthily, current researches around co-amorphous system (CAS) are mostly focused on preparation and characterization of these systems, but more detailed investigations of their supersaturation ("spring-parachute" process), stability, in vivo bioavailability and molecular mechanisms are inadequate and need to be clarified. In present study, we chose pharmacological relevant BCS II drugs to fabricate and characterize "felodipine-indomethacin" CAS. To enrich the current inadequate but key knowledge on CAS studies, we carried out following highlighted investigations including dissolution/solubility, semi-continuous "spring-parachute" process, long-term stability profile of amorphous state, in vivo bioavailability and underlying molecular mechanisms (molecular interaction, molecular miscibility and crystallization inhibition). Generally, the research provides some key information in the field of current "drug-drug" CAS supersaturable formulations.</AbstractText>
          <CopyrightInformation>Copyright Â© 2021. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Ya-Wei</ForeName>
            <Initials>YW</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hong-Mei</ForeName>
            <Initials>HM</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Bai-Ji</ForeName>
            <Initials>BJ</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hao</LastName>
            <ForeName>Cheng-Yi</ForeName>
            <Initials>CY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>He-Yun</ForeName>
            <Initials>HY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guan</LastName>
            <ForeName>Jiao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Jian-Hui</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Xian-Rong</ForeName>
            <Initials>XR</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Nian-Qiu</ForeName>
            <Initials>NQ</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China. Electronic address: shinianqiu2009@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Eur J Pharm Biopharm</MedlineTA>
        <NlmUniqueID>9109778</NlmUniqueID>
        <ISSNLinking>0939-6411</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OL961R6O2C</RegistryNumber>
          <NameOfSubstance UI="D015736">Felodipine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>XXE1CET956</RegistryNumber>
          <NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003460" MajorTopicYN="N">Crystallization</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004338" MajorTopicYN="Y">Drug Combinations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015736" MajorTopicYN="N">Felodipine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Molecular mechanisms</Keyword>
        <Keyword MajorTopicYN="N">Stability</Keyword>
        <Keyword MajorTopicYN="N">Supersaturating drug delivery systems (SDDS)</Keyword>
        <Keyword MajorTopicYN="N">âDrug-drugâ co-amorphous systems (CAS)</Keyword>
        <Keyword MajorTopicYN="N">âSpring-parachuteâ process</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>13</Day>
          <Hour>20</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34119671</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejpb.2021.05.030</ArticleId>
        <ArticleId IdType="pii">S0939-6411(21)00169-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34119671</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>12</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1873-3441</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>166</Volume>
            <PubDate>
              <Year>2021</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V</Title>
          <ISOAbbreviation>Eur J Pharm Biopharm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>"Felodipine-indomethacin" co-amorphous supersaturating drug delivery systems: "Spring-parachute" process, stability, in vivo bioavailability, and underlying molecular mechanisms.</ArticleTitle>
        <Pagination>
          <StartPage>111</StartPage>
          <EndPage>125</EndPage>
          <MedlinePgn>111-125</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejpb.2021.05.030</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0939-6411(21)00169-7</ELocationID>
        <Abstract>
          <AbstractText>Amorphous solid dispersions (ASD) are one of most commonly used supersaturating drug delivery systems (SDDS) to formulate insoluble active pharmaceutical ingredients. However, the development of polymer-guided stabilization of ASD systems faces many obstacles. To overcome these shortcomings, co-amorphous supersaturable formulations have emerged as an alternative formulation strategy for poorly soluble compounds. Noteworthily, current researches around co-amorphous system (CAS) are mostly focused on preparation and characterization of these systems, but more detailed investigations of their supersaturation ("spring-parachute" process), stability, in vivo bioavailability and molecular mechanisms are inadequate and need to be clarified. In present study, we chose pharmacological relevant BCS II drugs to fabricate and characterize "felodipine-indomethacin" CAS. To enrich the current inadequate but key knowledge on CAS studies, we carried out following highlighted investigations including dissolution/solubility, semi-continuous "spring-parachute" process, long-term stability profile of amorphous state, in vivo bioavailability and underlying molecular mechanisms (molecular interaction, molecular miscibility and crystallization inhibition). Generally, the research provides some key information in the field of current "drug-drug" CAS supersaturable formulations.</AbstractText>
          <CopyrightInformation>Copyright Â© 2021. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Ya-Wei</ForeName>
            <Initials>YW</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Hong-Mei</ForeName>
            <Initials>HM</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Bai-Ji</ForeName>
            <Initials>BJ</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hao</LastName>
            <ForeName>Cheng-Yi</ForeName>
            <Initials>CY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>He-Yun</ForeName>
            <Initials>HY</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guan</LastName>
            <ForeName>Jiao</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Jin</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Bo</ForeName>
            <Initials>B</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cai</LastName>
            <ForeName>Jian-Hui</ForeName>
            <Initials>JH</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qi</LastName>
            <ForeName>Xian-Rong</ForeName>
            <Initials>XR</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shi</LastName>
            <ForeName>Nian-Qiu</ForeName>
            <Initials>NQ</Initials>
            <AffiliationInfo>
              <Affiliation>School of Pharmacy, Jilin Medical University, Jilin City 132013, Jilin Province, China. Electronic address: shinianqiu2009@163.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>06</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Eur J Pharm Biopharm</MedlineTA>
        <NlmUniqueID>9109778</NlmUniqueID>
        <ISSNLinking>0939-6411</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000700">Analgesics</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000959">Antihypertensive Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OL961R6O2C</RegistryNumber>
          <NameOfSubstance UI="D015736">Felodipine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>XXE1CET956</RegistryNumber>
          <NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000959" MajorTopicYN="N">Antihypertensive Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003460" MajorTopicYN="N">Crystallization</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004338" MajorTopicYN="Y">Drug Combinations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016503" MajorTopicYN="N">Drug Delivery Systems</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015736" MajorTopicYN="N">Felodipine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Molecular mechanisms</Keyword>
        <Keyword MajorTopicYN="N">Stability</Keyword>
        <Keyword MajorTopicYN="N">Supersaturating drug delivery systems (SDDS)</Keyword>
        <Keyword MajorTopicYN="N">âDrug-drugâ co-amorphous systems (CAS)</Keyword>
        <Keyword MajorTopicYN="N">âSpring-parachuteâ process</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>13</Day>
          <Hour>20</Hour>
          <Minute>41</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34119671</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ejpb.2021.05.030</ArticleId>
        <ArticleId IdType="pii">S0939-6411(21)00169-7</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
